• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Alzheimer’s Disease imaging biomarkers slightly improve prediction of memory decline

byDaniel Fisher
June 21, 2019
in Chronic Disease, Imaging and Intervention, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this prospective cohort, Alzheimer’s Disease biomarkers derived from imaging, namely amyloid, tau, and cortical thickness estimates, had a moderate impact in predicting memory decline compared to a clinical model.

2. Patients that were positive for amyloid and at least one other biomarker had a faster rate of decline than other groups.

Evidence Rating Level: 2 (Good)

Study Rundown: As numerous clinical trials to treat Alzheimer’s Disease (AD) have failed, researchers have posited that early detection and treatment may be necessary to achieve clinically meaningful improvements. The National Institute of Aging and Alzheimer’s Association created an Amyloid, Tau, and Cortical Thickness (ATN) scoring system that uses imaging-based biomarkers to estimate dementia risk, though it is unclear if these biomarkers are useful for predicting the rate of memory decline. In this prospective cohort, ATN biomarkers had a significant but moderate impact in predicting memory decline compared to a clinical model. Patients that were A+T+N+, A+T+N-, and A+T-N+ had more rapid memory decline than other groups. ATN classifications were relatively stable over a period of a few years.

Though the ATN system was able to outperform the clinical model, the marginal increase in predictive power suggests that these biomarkers may still not be optimal for understanding risk associated with AD-related memory loss. Limitations, however, include the relatively short nature of the study over a half decade compared to the decades long process of AD pathogenesis, sole focus on memory decline and not other dementia symptoms, and a highly homogeneous population ethnically.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 6

#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer’s disease compared to placebo

Lecanemab may slow cognitive decline in early Alzheimer’s disease

Relevant Reading: National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease

In-Depth [prospective cohort]: 480 participants older than 60 years of age were recruited to the Mayo Clinic Study of Aging (MCSA) from Olmstead County, Minnesota (99% self-reported as white) and were randomly selected by 10-year age and sex strata so that men and women were represented equally. Patients without medical contraindication were invited to participate in imaging studies from April 2016 to November 2017 and had at least one follow-up evaluation before November 2018. Patients underwent amyloid and tau PET imaging, MRI to determine cortical thickness, and clinical evaluation, including age, sex, education, APOE4 status, and composite cardiovascular and metabolic conditions score. A numeric composite of memory function composed of the Wechsler Memory Scale–Revised Logical Memory–II (delayed recall), Wechsler Memory Scale–Revised Visual Reproduction–II (delayed recall), and Auditory Verbal Learning Test (delayed recall) was used as the primary endpoint and was represented by z-score using the standard deviation of the population. In the clinical prediction model, age and APOE4 status were associated with faster rates of cognitive decline (p < 0.05) while sex, education, and cardiovascular/metabolic status were not (p > 0.05). While the clinical model correlated with memory z-scores at r2 of 0.26, the ATN model offered a significant but modest improvement at r2 of 0.31 (p < 0.001). A+T+N+, A+T+N-, and A+T-N+ had greater rates of cognitive decline then the other 5 groups (p = 0.002). 88 patients had imaging follow-up at a median of 15 months later, and ATN status remained stable in 82% of these patients. A and T classifications were very stable at 98% and 97%, respectively, while N measures were stable at 84%.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s diseaseamyloid plaquecortical thicknessdementiamemory declinetau protein
Previous Post

Post-procedure stroke rates stable in TAVR patients in United States

Next Post

#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 6

January 13, 2023
#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer’s disease compared to placebo
StudyGraphics

#VisualAbstract: Lecanemab reduced cognitive and functional decline in early Alzheimer’s disease compared to placebo

January 12, 2023
Free alternatives comparable to Mini-Mental State Examination
Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

January 10, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

January 11, 2023
Next Post
#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

#Visual Abstract: Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

Quick Take: Evaluating the impact of community health volunteer home visits on child diarrhea and fever in the Volta Region, Ghana

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options